NorthStar Medical Radioisotopes has entered into a multi-year strategic services agreement with QSA Global, which specializes in radioactive source manufacturing and medical radiochemical services, the company announced today.

According to a release, QSA Global will process legacy Ra-226 on behalf of NorthStar. Then, following irradiation and processing by NorthStar to produce n.c.a. Ac-225, the recovered radium will be returned to QSA Global for recycling into new targets.

“This multi-year agreement with QSA Global strengthens our supply chain with a reliable, high-quality supply of Ra-226 targets critical to our n.c.a. Ac-225 production capabilities,” NorthStar President and CEO Dr. Frank Scholz said in a statement. “By ensuring consistent access to these vital starting materials, we can confidently meet growing demand within the industry.”

Financial terms were not disclosed.